Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Chunmei Yang, Liping Mao, Juying Wei, Wanzhuo Xie, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Liya Ma, Yinjun Lou, Huafeng Wang, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2024-202298

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Min Yang, De Zhou, Jian Huang, Liping Mao, Yinjun Lou, Wanzhuo Xie, Jie Jin

Blood (2024) 144 (Supplement 1): 6076.

https://doi.org/10.1182/blood-2024-210439

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia

Yinjun Lou, Jie Jin, Hongyan Tong, Shanshan Suo, Huafeng Wang, Liping Mao, Haitao Meng, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2024-209944

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Ying Huang, Yanan Zhu, Xiang Zhang, Xuewu Zhang, Juying Wei, Xingnong Ye, Yinjun Lou, Min Yang, Chunmei Yang, Wanzhuo Xie, Haitao Meng, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2024-205842

Published: 2024

Journal Articles

Impact of Different Therapeutic Regimen on Prognosis in CEBPA bZIP-Inf Acute Myeloid Leukemia

Jiajia Pan, Nianci Chen, Liping Mao, Yinjun Lou, Yi Zhang, Shanshan Suo, Yile Zhou, Chenying Li, Xia Li, Xueying Yang, Qing Ling, Wenle Ye, Xiangjie Lin, Huafeng Wang, Jie Jin

Blood (2024) 144 (Supplement 1): 4274.

https://doi.org/10.1182/blood-2024-211698

Published: 2024

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2023-186048

Published: 2023

Journal Articles

Venetoclax Plus ‘2 + 5‘ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis

Jiajia Pan, Huafeng Wang, Liping Mao, Yinjun Lou, Yanling Ren, Xingnong Ye, Honghu Zhu, Min Yang, Jiejing Qian, Jie Jin

Blood (2023) 142 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2023-180770

Published: 2023

Journal Articles

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gaixiang Xu, Yinjun Lou, Huafeng Wang, Wen-Juan Yu, Liping Mao, Jian Huang, Chenying Li, Shanshan Suo, Hongyan Tong, Jie Jin

Blood (2023) 142 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2023-187130

Published: 2023

Journal Articles

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Nianci Chen, Jiajia Pan, Yile Zhou, Liping Mao, Yinjun Lou, Jiejing Qian, Gaixiang Xu, Juying Wei, De Zhou, Lihong Shou, Huang Li, Minchao Yan, Hui Zeng, Cuihua Fan, Gongqiang Wu, Weiying Feng, Hongyan Tong, Jie Jin, Huafeng Wang

Blood (2023) 142 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2023-182806

Published: 2023

Journal Articles

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

Blood (2022) 140 (Supplement 1): 2263–2264.

https://doi.org/10.1182/blood-2022-170604

Published: 2022

Journal Articles

Venetoclax Plus "2 + 5" Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

Huafeng Wang, Yiyi Yao, Liping Mao, Yinjun Lou, Yanling Ren, Xingnong Ye, Min Yang, Liya Ma, Yi Zhang, Yile Zhou, Xin Huang, Yungui Wang, Huan Xu, Hongyan Tong, Hong-hu Zhu, Jie Jin

Blood (2022) 140 (Supplement 1): 3350–3351.

https://doi.org/10.1182/blood-2022-165738

Published: 2022

Journal Articles

Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single Center

Yinjun Lou, Gaixiang Xu, Huafeng Wang, Liping Mao, Hongyan Tong, Jie Jin

Blood (2022) 140 (Supplement 1): 11683–11684.

https://doi.org/10.1182/blood-2022-165879

Published: 2022

Journal Articles

Realgar Indigo Formula Plus ATRA As Postremission Treatment in an Rral and Chemo-Free Model for High-Risk Acute Promyelocytic Leukemia Patients: A Prospective, Multicenter, Phase II Study

Hong-hu Zhu, Ya-fang Ma, Suning Chen, Ying Lu, Jiang Huang, Huai-Yu Wang, Xiaohua Xu, Bing-Shou Xie, Yinjun Lou, Jie Jin

Blood (2021) 138 (Supplement 1): 873.

https://doi.org/10.1182/blood-2021-149141

Published: 2021

Journal Articles

A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia

Jiejing Qian, Jieyu Xu, Qing Hong, Yinjun Lou, Liping Mao, Weilai Xu, Min Yang, Wenjuan Yu, Haitao Meng, Wenyuan Mai, Xiujing Ye, Honghu Zhu, Jie Jin

Blood (2021) 138 (Supplement 1): 4414.

https://doi.org/10.1182/blood-2021-149523

Published: 2021

NARROW

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Impact of Different Therapeutic Regimen on Prognosis in CEBPA bZIP-Inf Acute Myeloid Leukemia

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Venetoclax Plus ‘2 + 5‘ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

Venetoclax Plus "2 + 5" Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single Center

Realgar Indigo Formula Plus ATRA As Postremission Treatment in an Rral and Chemo-Free Model for High-Risk Acute Promyelocytic Leukemia Patients: A Prospective, Multicenter, Phase II Study

A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only